menu
    • menu
    [{"orgOrder":0,"company":"CareDx","sponsor":"Eledon Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Tegoprubart","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase II","graph3":"CareDx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CareDx \/ CareDx","highestDevelopmentStatusID":"8","companyTruncated":"CareDx \/ CareDx"},{"orgOrder":0,"company":"CareDx","sponsor":"Eledon Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"Tegoprubart","moa":"CD40 ligand","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"CareDx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CareDx \/ Eledon Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"CareDx \/ Eledon Pharmaceuticals"},{"orgOrder":0,"company":"CareDx","sponsor":"CareDx","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Mycophenolate Mofetil","moa":"Inosine-5'-monophosphate dehydrogenase (IMPDH)","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"CareDx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CareDx \/ CareDx","highestDevelopmentStatusID":"11","companyTruncated":"CareDx \/ CareDx"},{"orgOrder":0,"company":"CareDx","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"VIR-7831","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CareDx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CareDx \/ Vir Biotechnology","highestDevelopmentStatusID":"10","companyTruncated":"CareDx \/ Vir Biotechnology"},{"orgOrder":0,"company":"CareDx","sponsor":"UT Southwestern Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Belatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Undisclosed","graph2":"Phase IV","graph3":"CareDx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CareDx \/ CareDx","highestDevelopmentStatusID":"11","companyTruncated":"CareDx \/ CareDx"},{"orgOrder":0,"company":"CareDx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Mycophenolate Mofetil","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"CareDx","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CareDx \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"CareDx \/ Undisclosed"},{"orgOrder":0,"company":"CareDx","sponsor":"TC BioPharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Partnership","leadProduct":"OmnImmune","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"CareDx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CareDx \/ TC BioPharm","highestDevelopmentStatusID":"8","companyTruncated":"CareDx \/ TC BioPharm"}]

    Find Clinical Drug Pipeline Developments & Deals by CareDx

    Menu

    CareDx

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CareDx

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed

                            CareDx

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OmnImmune

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : TC BioPharm

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            CareDx, TC BioPharm Partner on AlloCell Monitoring for Cell Therapy Trial

                            Details : The partnership aims to support ACHIEVE clinical trial using AlloCell to evaluate the efficacy and effectiveness of TCB008, an allogeneic gamma-delta T-cell therapy for patients with AML or MDS.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            December 11, 2024

                            Lead Product(s) : OmnImmune

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : TC BioPharm

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            CareDx

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed

                            CareDx

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mycophenolate Mofetil

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            KidneyCare Immuno-optimization in Renal Allografts (KIRA)

                            Details : MMF is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 21, 2022

                            Lead Product(s) : Mycophenolate Mofetil

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            CareDx

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed

                            CareDx

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tegoprubart

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Recipient : Eledon Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Eledon Pharmaceuticals CEO David-Alexandre C. Gros, M.D., to Present at CareDx Virtual Transplant Innovation D...

                            Details : Presentation to focus on potential use of AT-1501 in kidney transplantation as well as research collaboration between Eledon and CareDx to help assess the efficacy of Eledon’s investigational AT-1501 for the prevention of rejection in upcoming kidney t...

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            November 04, 2021

                            Lead Product(s) : Tegoprubart

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Recipient : Eledon Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            CareDx

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed

                            CareDx

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tegoprubart

                            Therapeutic Area : Immunology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Eledon Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            CareDx and Eledon Pharmaceuticals Announce Collaborative Research Agreement

                            Details : Collaboration agreement provides Eledon with access to CareDx’s best-in-class technologies, including the study to evaluate the safety, efficacy and pharmacokinetics of AT-1501 in de novo kidney transplant recipients.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            October 19, 2021

                            Lead Product(s) : Tegoprubart

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Eledon Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            CareDx

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed

                            CareDx

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mycophenolate Mofetil

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Recipient : University of California, Davis

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients

                            Details : Mycophenolate Mofetil is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            September 29, 2021

                            Lead Product(s) : Mycophenolate Mofetil

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Recipient : University of California, Davis

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            CareDx

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed

                            CareDx

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VIR-7831

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Vir Biotechnology

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            CareDx Supports Vir Biotechnology’s Clinical Trial Recruitment Efforts for COMET-ICE

                            Details : The ongoing trial is evaluating VIR-7831, a fully human anti-SARS-CoV-2 monoclonal antibody, for the early treatment of COVID-19 in adults at high risk of hospitalization.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            March 23, 2021

                            Lead Product(s) : VIR-7831

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Vir Biotechnology

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            CareDx

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed

                            CareDx

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Belatacept

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase IV

                            Recipient : UT Southwestern Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Use of DNA Testing to Help Transition Kidney Transplant Recipients to Belatacept-only Immunosuppression

                            Details : Belatacept is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            March 08, 2021

                            Lead Product(s) : Belatacept

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase IV

                            Recipient : UT Southwestern Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth